Drugs for Type 2 Diabetes
March 1, 2014 (Issue: 139)
The goal of drug therapy for type 2 diabetes is to achieve and
maintain a near-normal A1C concentration without
inducing hypoglycemia; the target is generally an A1C
of 10,000 patients with type 2 diabetes,
with or at high-risk for cardiovascular disease, found
that treating patients intensively with antihyperglycemic
drugs to an A1C target of 6.0% for a mean of 3.7 years
did not significantly reduce the incidence of major
cardiovascular events (the primary endpoint) and was
associated with increased all-cause mortality compared
to patients treated to an A1C target of 7.0-7.9%. An
A1C target of 7-8% may be prudent in older patients
and in those with underlying cardiovascular disease,
severe hypoglycemia, or multiple diabetes-related
complications
...
more
1. American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014; 37 (suppl 1):s14.
2. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818.
3. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.
4. W Duckworth et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129.
5. JS Skyler et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119:351.
6. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145.
7. SE Kahn et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427.
8. RR Holman et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.
9. WR Lu et al. Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother 2013; 47:1488.
10. AV Hernandez et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11:115.
11. SE Nissen and K Wolski. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457.
12. KW Mahaffey et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166:240.
13. In brief: rosiglitazone (Avandia) unbound. Med Lett Drugs Ther 2014; 56:12.
14. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47:45.
15. B Gallwitz et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012; 379:2270.
16. Extended-release exenatide (Bydureon) for type 2 diabetes. Med Lett Drugs Ther 2012; 54:21.
17. T Blevins et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96:1301.
18. M Davies et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 2013; 36:1368.
19. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.
20. JB Buse et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381:117.
21. PC Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013; 36:2118.
22. Alogliptin (Nesina) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:41.
23. Linagliptin (Tradjenta) – a new DPP-4 inhibitor for type 2 diabetes. Med Lett Drugs Ther 2011; 53:49.
24. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85.
25. BM Scirica et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317.
26. WB White et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327.
27. S Singh et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173:534.
28. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available at www.fda. gov. Accessed February 18, 2014.
29. MA Nauck. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013; 36:2126.
30. Canagliflozin (Invokana) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:37.
31. Dapagliflozin (Farxiga) for type 2 diabetes. Med Lett Drugs Ther 2014; 56:13.
32. D Vasilakou et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159:262.
33. Pramlintide (Symlin) for diabetes. Med Lett Drugs Ther 2005; 47:43.
34. In brief: A new indication for colesevelam (Welchol). Med Lett Drugs Ther 2008; 50:33.
35. CP Ooi and SC Loke. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review. Diabet Med 2014; 31:2.
36. Bromocriptine (Cycloset) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:97.
37. JM Gaziano et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc 2012; 1:e002279.
38. SR Singh et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180:385.
39. Rapid-acting insulin analogs. Med Lett Drugs Ther 2009; 51:98.
40. Insulin glulisine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther 2006; 48:33.
41. P Aschner et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012; 379:2262.
42. Insulin detemir (Levemir), a new long-acting insulin. Med Lett Drugs Ther 2006; 48:54.
43. K Hermansen et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29:1269.
44. L Meneghini et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15:729.
45. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.
46. RR Holman et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Gain access through your organization
